EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A Dose of Perspective

Nasir A Shah iD, Rui Du iD, Brendon L Neuen iD, Adeera Levin iD, Vivek Jha iD, Hiddo J L Heerspink iD, Sradha S Kotwal iD, CAPTIVATE investigators

Kidney360 · 2026-08 · 7 (8) · 1772-1780

DOI: 10.34067/kid.0000001227 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Kidney360, online erschienen am 02.06.2026. Verfasst von Nasir A Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Attitude of Health Personnel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Both patients and clinicians were broadly supportive of combination therapy in CKD. Implementation remains the main challenge, especially how to start and sequence drugs.

Background

CKD affects approximately 15% of adults and remains a major cause of kidney failure and cardiovascular events. Several newer drug classes—sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, and endothelin receptor antagonists—provide additional kidney and cardiovascular protection added to standard-of-care renin-angiotensin system inhibition, but the real-world acceptability of using these agents in combination is uncertain. To evaluate the willingness of people with CKD and clinicians to use multidrug combination therapy and to characterize perceived benefits, risks, and barriers to implementation.

Methods

We conducted a cross-sectional, descriptive, semiquantitative online survey of adults with CKD and clinicians who prescribe CKD therapies. Parallel questionnaires captured demographics, current treatment, prior experience with multidrug regimens, willingness to receive or prescribe combination therapy, and ranked priorities and concerns.

Results

One hundred forty-two people living with CKD and 317 clinicians completed the survey. Most CKD respondents resided in Australia or the United Kingdom; most surveyed clinicians were hospital-based physicians. Willingness to use multiple agents to reduce CKD progression was high (113/142, 80% “yes”; 27/142, 19% “maybe”). Respondents with CKD prioritized reducing CKD progression and preventing complications, while highlighting side effects, long-term safety, and drug-drug interactions as key concerns; pill burden and cost were less frequently prioritized. Clinicians strongly supported combination therapy in a trial context (300/317, 95%) and reported basing prescribing on guideline recommendations, trial evidence, kidney function, and albuminuria. Principal barriers were risks of hyperkalemia and acute eGFR decline, intensified biochemical monitoring, and cost/limited access. Most clinicians preferred staggered rather than simultaneous initiation, typically starting with a sodium-glucose cotransporter 2 inhibitor as the first add-on to background renin-angiotensin system inhibitor therapy.

Conclusions

People with CKD and clinicians support multidrug combination therapy, but concerns regarding safety, monitoring burden, and affordability must be addressed to enable routine implementation and large-scale trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAttitude of Health PersonnelHumansCross-Sectional StudiesFemaleDrug Therapy, CombinationMaleMiddle AgedAdultAgedMineralocorticoid Receptor AntagonistsSurveys and QuestionnairesSodium-Glucose Transporter 2 InhibitorsAustraliaEndothelin Receptor AntagonistsGlucagon-Like Peptide-1 Receptor AgonistsPractice Patterns, Physicians'

Stichwörter der Autor:innen

CKDclinical trialpatient-centered carerandomized controlled trials

Substanzen

Mineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsEndothelin Receptor AntagonistsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
  • Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
  • School of Basic Medical Science, Tsinghua Medicine, Tsinghua University, Beijing, China.
  • Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
  • The George Institute for Global Health, New Delhi, India.

ORCID-Profile: Nasir A Shah, Rui Du, Brendon L Neuen, Adeera Levin, Vivek Jha, Hiddo J L Heerspink, Sradha S Kotwal

Zitieren

APA

Shah, N. A., Du, R., Neuen, B. L., Levin, A., Jha, V., Heerspink, H. J. L., Kotwal, S. S., & CAPTIVATE investigators (2026). A Dose of Perspective. Kidney360, 7(8), 1772-1780. https://doi.org/10.34067/kid.0000001227

Vancouver

Shah NA, Du R, Neuen BL, Levin A, Jha V, Heerspink HJL, et al. A Dose of Perspective. Kidney360. 2026;7(8):1772-1780. doi:10.34067/kid.0000001227

BibTeX
@article{Shah2026,
  author = {Shah, Nasir A and Du, Rui and Neuen, Brendon L and Levin, Adeera and Jha, Vivek and Heerspink, Hiddo J L and Kotwal, Sradha S and CAPTIVATE investigators, CAPTIVATE investigators},
  title = {A Dose of Perspective},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {8},
  pages = {1772--1780},
  doi = {10.34067/kid.0000001227}
}
Kostenlos starten →